Attend our independent satellite symposium at ASCO GU 2025 to delve into the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Expert panelists will discuss guideline-driven treatment strategies across RCC histologies and the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Attendees will gain actionable insights for personalizing RCC care and improving patient outcomes.
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
Join us at ASCO GU 2025 to explore risk stratification, latest clinical evidence, and personalized, multidisciplinary strategies in advanced RCC care.
Live
Meeting
1.50 available credits
Information
February 13, 2025
07:00 PM - 09:00 PM PT
Marriott Marquis San Francisco
780 Mission St., Room: Salons 1-6, San Francisco, California, United States
Share
Share
Share
Share this program on:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Eric Jonasch, MD
Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
No relevant financial relationships have been reported at this time.
Faculty:
Bradley McGregor, MD
Medical Oncologist
Director of Clinical Research
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, MA
No relevant financial relationships have been reported at this time.
Ulka Vaishampayan, MD
Beverly Mitchell MD Research Professor of Medicine
University of Michigan
Ann Arbor, MI
Dr. Vaishampayan has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Bayer, BMS, Gilead, Janssen, Mural, Pfizer, Sumitomo
Research: Merck
Reviewers/Content Planners/Authors:- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the role of risk stratification models for newly diagnosed patients with advanced RCC of clear cell histology
- Analyze practice-informing evidence from clinical trials and real-world studies across RCC histologies
- Develop guideline-concordant, multidisciplinary treatment strategies within a shared decision-making context for patients with advanced RCC
- Utilize a multidisciplinary approach to the monitoring and management of adverse events experienced by patients with advanced RCC
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and urologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with renal cell carcinoma.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by independent educational grants from Exelixis and Merck.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Overview
Attend our independent satellite symposium at ASCO GU 2025 to delve into the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Expert panelists will discuss guideline-driven treatment strategies across RCC histologies and the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Attendees will gain actionable insights for personalizing RCC care and improving patient outcomes.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Eric Jonasch, MD
Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
No relevant financial relationships have been reported at this time.
Faculty:
Bradley McGregor, MD
Medical Oncologist
Director of Clinical Research
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, MA
No relevant financial relationships have been reported at this time.
Ulka Vaishampayan, MD
Beverly Mitchell MD Research Professor of Medicine
University of Michigan
Ann Arbor, MI
Dr. Vaishampayan has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Bayer, BMS, Gilead, Janssen, Mural, Pfizer, Sumitomo
Research: Merck
Reviewers/Content Planners/Authors:- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the role of risk stratification models for newly diagnosed patients with advanced RCC of clear cell histology
- Analyze practice-informing evidence from clinical trials and real-world studies across RCC histologies
- Develop guideline-concordant, multidisciplinary treatment strategies within a shared decision-making context for patients with advanced RCC
- Utilize a multidisciplinary approach to the monitoring and management of adverse events experienced by patients with advanced RCC
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and urologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with renal cell carcinoma.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by independent educational grants from Exelixis and Merck.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Susana Campos, MD, MPH
Nicoletta Colombo, MD
Ritu Salani, MD, MBA
1.00 credit 10 episodes
Tanya Dorff, MD
Rana McKay, MD
0.75 credits 7 episodes
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program creditsIgnacio Duran, MD
Wenxin Xu, MD
1.25 program creditsGuideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 program creditSusana Campos, MD, MPH
Ritu Salani, MD, MBA
1.00 program credit